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A decline in breast cancer incidence has been attributed to the reduction in hormone
replacement therapy (HRT) prescriptions since the publication of the landmark WHIT paper
in 2003. Concurrently, a relationship between HRT and cerebrovascular disease incidence
has also been suggested. No generalized analysis of HRT prescription rates and breast
cancer incidence rates that included more than seven years of data. We hypothesized that
detailed analysis of SEER data would clarify the relationship between HRT use and breast
cancer incidence. Given the large decline in HRT prescription rates uncovered, analyses of
potential complications were also conducted, with the understanding that a small effect or
one limited to a subpopulation, such as a single race, might not be detected.
Methods
Incidence rates (per 100,000 women) and standard errors for ductal and lobular breast car-
cinomas, and endometrioid /endometrial carcinomas in women over 50 years were
obtained from the Surveillance, Epidemiology, and End Results (SEER) database 1992–
2012. From the Medical Expenditure Panel Survey 1996–2012 weighted counts and stan-
dard errors of hormone replacement therapy (HRT) prescriptions for women over 50 years
were obtained. Using the National Hospital Discharge Survey (NHDS), 1996–2010
weighted counts and standard errors of femoral neck fractures, total hip replacements,
acute myocardial infarctions, and cerebral infarctions were obtained for 50+ year men and
women. Weighted counts and standard errors were divided by US census figures and multi-
plied by 100,000. Joinpoint regression was used to analyze rates.
Main Results
Beginning 2001, HRT prescription rates dropped dramatically, 2001–2012 AAPC -14.9
(95% CI -17.4, -12.4). Breast cancer rates, which began to decline in 1999, increased after
2003; 2012 rates were similar to those seen in 2001 for both ductal, AAPC 0.1 (-0.4, 0.6)
and lobular, AAPC 0.5 (-0.4, 1.5), carcinoma. Endometrial carcinoma rates increased,
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2001–2012 AAPC 3.5 (3.1, 3.8), arguing against a negative effect of HRT discontinuation of
endometrial carcinoma. Tests for parallelism failed to detect APC differences among gen-
ders for femoral neck fractures (P = 0.24), for total hip replacements (P = 0.11), for myocar-
dial infarctions (P = 0.10), or for cerebral infarctions (P = 0.19), precluding any assignment
of general effect on these disorders by HRT.
Conclusions
Using SEER data, we demonstrated that changes in breast cancer rates cannot be
explained by HRT prescription rate changes.
Introduction
After a meta-analysis of epidemiological studies suggested that hormone replacement therapy
(HRT) was a risk factor for breast cancer,[1] a prospective trial, the women’s health initiative
randomized trial (WHIT), was conducted; results were abandoned after the data revealed a sta-
tistically significant difference in risk, reported in 2003.[2] A New England Journal of Medicine
article in 2007 found a post 2003 decline in breast cancer incidence, which it deemed evidence
of a confirmation of the findings of the 2003 WHIT paper.[3] Replies to this article suggested
alternative conclusions.[4–6] A second report fromWHIT suggested a connection between
cerebrovascular accidents and HRT.[7] A third re-analysis of the data[8] was said to support
the prior analysis, while suggesting that SEER data lent support to their results. Extensive anal-
ysis of SEER data, however, was lacking in that report. In addition, in the third report, for both
the Estrogen+ Progestin (E+P) and the estrogen (E) alone trials, the treated groups had hazard
ratios less than 1 (protective) for at least 2 years, which indicates that were HRT positively asso-
ciated with breast cancer rate, the effect is unlikely to be immediate. Moreover, although poten-
tial contributions to changes as respects hip fractures and cardiovascular diseases were
evaluated in a separate analyses of WHIT data,[9] no generalized analysis of these changes has
been done as respects changes in HRT prescription rates.
This analysis aims at using population level data, to confirm/address: 1) is there reason to
believe, as suggested by the third WHIT report,[8] that changes in breast cancer incidence rates
reflect changes in HRT prescription rates? 2) is there reason to believe that changes in HRT
rates had a positive or negative impact on changes in rates of hip fractures, hip replacements,
myocardial infarctions or cerebrovascular accidents?
Materials and Methods
The Institutional Review Board at Texas Tech University Health Sciences Center has in place a
policy of not reviewing projects involving publicly available data; publicly available data for
this study was obtained from the sources listed below, patient records/information for which
had been anonymized and de-identified prior to analysis.
The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer
Institute (NCI) collects cancer incidence data from population-based cancer registries covering
about a fourth of the US population.[10] SEER 13 included 1992–2012 data from the Atlanta,
Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget
Sound, Utah, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Tumor
Registries.[11] The SEERstat program[12] obtained from the SEER 13 registries database[13]
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1992–2012 incidence rates and standard errors for women 50+ y, histologically proven invasive
ductal carcinoma (ICD-O-3 8500/3) and lobular carcinoma (ICD-O-3 8520/3) of the breast
and endometrioid carcinoma (ICD-0-3 8380/3) of the uterus. For ductal and separately for lob-
ular carcinoma, incidence rates and standard errors were obtained for races White and Black,
as well as age groups, 50–59 y, 60–69 y, 70–79 y, 80+ y; the selection of these decades was to
parallel the WHIT study population. Rates per 100,000, their standard errors, and the associ-
ated raw data are supplied in Table A in S1 Table.
Following the review of a report from the Medical Expenditure Panel Survey,[14] a work
order was issued to obtain estimates (weighted counts) and standard errors of hormone replace-
ment therapy (HRT) prescriptions for 50+ y women from all available years, 1996–2012;[15]
Therapeutic class and subclass were assigned to MEPS prescribed medicines using Multum Lex-
icon variables from Cerner Multum, Inc. MEPS prescribed medicines files were linked to the
Multum Lexicon database to obtain therapeutic class and subclass variables. The first choice in
the linking algorithm was chosen when assigning therapeutic classes and subclasses. For all
years of data, the following was used to define hormone replacement therapy drugs: therapeutic
class: Hormones; subclass: Sex Hormones; and sub subclasses: Estrogens, Progestins, and Sex
Hormone Combinations. Rates for weighted counts and their standard errors were divided by
US population values for women 50+ y as determined by the US Census and multiplied by
100,000 to obtain rates per 100,000 woman years and standard errors. Rates per 100,000, their
standard errors, and the associated raw data are supplied in Table A in S1 Table.
The incidence of femoral neck fractures (ICD-9 820.8), total hip replacements (ICD-9 8151),
acute myocardial infarctions (ICD-9 410.00–410.92), and cerebral infarctions (ICD-9 433.01,
433.11, 433.21, 433.31,433.81, 433.91, 434.01, 434.11, 434.91) was obtained via the National Hos-
pital Discharge Survey[16] for all available years, 1996–2010, for both men and women. For each
available year, weighted counts were obtained by a search for the ICD-9 codes for the condition/
procedure of interest. Relative standard errors for each weighted count were calculated using the
two parameters supplied for each year in the associated documentation, which were then multi-
plied by the weighted counts to yield standard errors. Weighted counts and their standard errors
were divided by US population values for women and for men 50+ y as determined by the US
Census and multiplied by 100,000 to obtain rates per 100,000 man|woman years. Rates per
100,000, their standard errors, and the associated raw data are supplied in Table A in S1 Table.
The Joinpoint Regression Program[17], with default settings, log linear regression, and grid
search method calculated estimates, standard errors, and 95% confidence intervals for join-
points, annual percentage changes (APC), and average annual percent changes (AAPC), as
well as tests of parallelism was used. Tests of parallelism were performed on the sexes with ref-
erence to femoral neck fractures, total hip replacements, myocardial infarctions, and cerebro-
vascular accidents, as a lack of difference in APC among the genders would imply a lack of
effect on those disorders from a large change in HRT prescription rates. Tests of parallelism
were also performed between lobular and ductal carcinoma, to see if it would be reasonable to
combine the two types of breast cancer, and for the age and racial subgroups of lobular and
ductal carcinoma to see a) if there were differences between subgroup APC’s and overall
APC’s, and b) to see if there were differences among the subgroups. Joinpoint estimated time
periods, APC (95% CI), AAPC (95% CI), and P values are displayed in Table B in S1 Table. R
3.0.1[18] drew the figure. Null hypotheses were rejected when P< 0.05.
Results
In Figs 1, 2 and 3, symbols lie at annual incidence rates. Line segment slopes are annual percent
changes (APC), solid when not zero (rates changed), dotted when rates might be constant.
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Segments meet at joinpoints, points where APC was estimated to have changed; the left graph
of Fig 1, of HRT prescriptions, had two joinpoints, a 2001 rate peak and a 2004 slowing of a
decline in rates. Dashed vertical grey lines at 2000 enable the reader to count years before and
after 2000 by noting the number of symbols between any point of interest and the grey line;
periods of greatest interest near the turn of the century.
Fig 1. Hormone replacement therapy (HRT) prescriptions, breast carcinomas, and endometrial carcinomas.
doi:10.1371/journal.pone.0138556.g001
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Fig 1 displays rates and APC for HRT prescriptions, for invasive breast cancer, and for
endometrioid carcinoma. Breast cancer rates peaked in 1999, thereafter declining for ductal
carcinoma, APC -4.5 (-6.8, -2.2), and lobular carcinoma, APC -5.6 (-8.3, -2.7). Rates increased
for ductal carcinoma, APC 1.1 (0.7, 1.5), beginning 2003 and for lobular carcinoma, APC 2.9
Fig 2. Femoral neck fractures, total hip replacements, myocardial infarctions, and cerebral infarctions.
doi:10.1371/journal.pone.0138556.g002
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(2.0, 3.9), beginning 2004. A test for parallelism showed that lobular carcinoma rates did not
parallel ductal carcinoma rates (P = 0.002); that joinpoints and APC for lobular carcinoma
were different from those for ductal carcinoma supports the differences seen in prior survival
[19] and molecular[20, 21] analyses. Endometrioid carcinoma increased throughout the period
Fig 3. Age and Race Subgroups as Respects Ductal and Lobular Carcinomas of the Breast).
doi:10.1371/journal.pone.0138556.g003
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of study; it did so at decreasing rates, with APC from 1992 until 1995 (1994, 1997) of 33.3 (23,
44.4) and, beginning 1998 (1997, 2012), of 3.5 (3.1, 3.8).
There was an extreme drop in HRT prescriptions beginning 2001 (95% CI 2000, 2002),
which then slowed beginning 2004. The overall magnitude can be expressed either as an AAPC
of -14.9 (95% CI -17.4, -12.4) or by saying that 2012 rates were 0.17 (0.12, 0.23) times those of
2001 rates. By contrast, for 2001–2012 rates for ductal carcinoma, AAPC 0.1 (-0.4, 0.6), and for
lobular carcinoma, AAPC 0.5 (-0.4, 1.5), were not found to have changed. Because lobular and
ductal carcinoma rates peaked in 1999, with the turning points of APR in 1999, breast cancer
rate peaks were considered to have occurred prior to the HRT rate peak. Were HRT and breast
cancer rates associated, then the incidence of breast cancer would most likely have been higher
in 2000 and 2001 because of the 2001 HRT; given a lag effect (according to the 3rd WHIT
report, a less than 1 hazard ratio for the first two years since randomization, for both the E+P
or E alone trials), breast cancer incidence should have been high even in 2002. However, Fig 1
does not show that type of relationship, raising questions as to its presence. After 2003, the
slope of HRT prescription rate is a little flatter than that from 2001–2003, however, the abso-
lute annual HRT prescription rate is still lower than that from 2001–2003. If HRT and breast
cancer rates were fully correlated, then breast cancer rate should have been be lower for 2003–
2010 than that from 2001–2003.
For endometrioid carcinoma rates, the 2001–2012 AAPC is the same as the 1999–2012
APC; 2012 rates were 1.46 (1.40, 1.51) times those of 2001 rates. The decline in HRT prescrip-
tions is not reflected by changes seen in endometrioid carcinoma rates.
Fig 2 shows annual rates and APC for national hospital discharge survey data. Tests for par-
allelism failed to detect APC differences among genders for femoral neck fractures (P = 0.24),
total hip replacements (P = 0.11), myocardial infarctions (P = 0.10), or cerebral infarctions
(P = 0.19). The lack of a difference implies the effect of HRT prescriptions on these disorders
cannot be very large at the level of a population of SEER size, since incidence rates of each con-
dition for the sex that does not receive HRT (i.e. men) parallel those of the sex that did receive
them. Femoral neck fracture rates decline throughout the study period, APC -3.6 (-4.7, -2.5);
this is potentially explicable by the overall increment in total hip replacement rates, AAPC 4.1
(0.9, 7.2) given that total hip replacement precludes femoral neck fractures unless hip replace-
ment is occasioned by the femoral neck fracture. Rates of myocardial infarction, AAPC -2.4
(-4.8, -0.03), decline over the entire period of study. Cerebral infarction rates first decline,
1996–2001 APC -4.6 (-7.8, -1.4), and then increase, 2001–2010 APC 2.5 (1.0, 4.0). Without tak-
ing into account the similarity of APC for stroke between men and women, it might be possible
to argue HRT has a protective effect as respects cerebrovascular accidents; however because the
2001–2010 rate increase is similar for men and women, that conclusion would not be justified.
Tests for parallelism show different findings for ductal and lobular carcinoma as respects
age groups. As compared with APC for the overall population, for ductal carcinoma no age
subgroup has similar APC (P< 0.05, for each analysis); for lobular carcinoma, except for 60–
60 y (P = 0.01), all age subgroups have similar APC (P> 0.05, for each analysis). As compared
with APC for 50–59 y, for ductal carcinoma APC for 60–69 y (P< 0.001) and 70–79 y
(P< 0.001) differ, while those for 80+ y are similar (P> 0.05). With respect to race, for both
ductal and lobular carcinoma, APC for Whites and Blacks differ from that for the overall popu-
lation and from one another (P< 0.05, for each analysis).
Fig 3 shows rates and APC by age and race subgroup for ductal and lobular carcinoma. If
HRT prescription rate changes occur more for younger than for older women, one would
expect to see any difference between 50–59 y and 60–69 y magnified for 70–79 y women. For
2003–2012 APC differences among decades show a trend indicating a larger increase among
older women—50–59 y 0.4 (-0.2, 0.9), 60–69 y 1.5 (0.9, 2.2), 70–79 y 1.9 (1.2, 2.6). For
Breast Cancer Rates, Hormone Replacement Therapy
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preceding periods, no magnification is present—50–59 y, 1999–2003, -4.4 (-7.1, -1.5), 60–69 y,
2000–2003. -4.6 (-11.8, 3.1), 70–79 y, 1998–2003, -4.6 (-6.8, -2.4). For lobular carcinoma,
results of parallelism tests do not support an age-related effect. Comparisons of the age groups
originally studied by WHIT,[2, 8] shows no evidence of an age related effect. For both ductal
and lobular carcinoma, the approach to equality between Black and White women in the last
period of analysis cannot be explained on a general effect of HRT on breast cancer incidence.
All subgroups showed rate peaks before 2001, except Black women with ductal carcinoma,
which never showed a rate peak.
Conclusions and Discussion
The epidemiological studies evaluated in 1997[1] found that women who had used HRT begin-
ning at age 50 had an extra 2 (95% CI 1, 3) breast cancers per 1,000 women after five years of
use, an extra 6 (3, 9) cancers after ten years use, and an extra 12 (5, 20) cancers after 15 years of
use. A prospective randomized trial, the Women’s health Initiative Randomized Trial (WHIT)
reported in 2003 a greater risk of breast cancer among patients being given estrogen progester-
one HRT than those who had not;[2] the study was abandoned after an average of 5.6 y and
showed an increase in risk of breast cancer, HR 1.24 (1.01, 1.54).
A 2007 report indicated that there had been a decline in breast cancer incidence in 2003,
and related this decline to discontinuation of post-menopausal hormone replacement therapy
(HRT).[3] Several limitations of generalized conclusions from this paper’s data were provi-
sioned in letters to the editor: Canadian breast cancer incidences peaked before 2003;[4] Scan-
dinavian rates of HRT use did not correlate with breast cancer incidence;[5] and estrogen
positive breast cancer rates were noted in the US to have peaked in 1999.[6]
A later trial of estrogen only HRT versus placebo by WHIT,[7] showed a long-term risk
reduction of breast cancer accorded to estrogen only HRT, HR 0.77 (0.62, 0.95) that was oppo-
site and nearly equivalent in magnitude to the differences documented in the prior studies. The
trial was abandoned, however, because of an increased number of cerebrovascular accidents in
the treatment arm;[9] no deleterious effect as respects myocardial infarction or hip fractures
was seen.
Provided the limitations of generalized analyses and survey data are taken into account,
these findings can be evaluated by examining changes in overall rates of the varying disorders.
The MEPS survey only included household survey data, was not verified with claims data, only
included outpatient prescription medicines in an outpatient setting, included both refills and
original prescriptions, and did not distinguish types of HRT. The NIHS survey data was calcu-
lated from codes submitted from billing, not from diagnoses submitted from a uniform popula-
tion of health care providers, did not include nursing home stays or office visits, and did not
distinguish first or second episodes of events. SEER data were from diagnoses rendered by
community and academic pathologists without central review, did not distinguish first from
second malignancies, and did not supply information as to the health status in general of the
associated population.
Because the databases are unlinked, no stratification as respects covariates could be
attempted. This disadvantage, however, is balanced by two factors. Because men did not receive
HRT, when the genders show parallel rates, then HRT cannot be plausibly said to explain
changes in those rates. Because breast cancer is so rare in men,[22] assessing parallelism
between gender rates was not a viable option. The results of parallelism tests indicate that,
given the extraordinary drop in HRT prescriptions, there is little or no reason to believe that
such drops influenced rates of femoral neck fractures, total hip replacements, myocardial
infarctions, or cerebral infarctions. Data was not available as respects the different formulations
Breast Cancer Rates, Hormone Replacement Therapy
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of HRT; because the drop in HRT rates was so large and because estrogen-only formulations
were said to provide long-term protection against breast cancer,[7] the separate analysis would
not have contributed to an understanding of why breast cancer rates increased after 2003.
The second advantage of the current analysis lies in the assessment of potential bad out-
comes of a drug or drug combination that shows marked increases or decreases in prescription
rates. As shown, none of the evaluated factors could be said to have been influenced by HRT.
Endometrioid carcinoma rates increased over the entire period of study, implying that the
HRT formulations used during the period of study did not play a prominent role. Because the
genders did not differ as respects the remaining factors, HRT cannot be said to have exhibited
a large influence on them; neither can it be said, from this analysis of disease markers, that
changes in other potential risk factors were different for men than for women.
Because the results conflict with the conclusions of both major WHIT evaluations,[2, 8]
some discussion is warranted specifically with respect to those articles. First, Fig 1 of the first
report[2] shows crossed cumulative incidence curves at 3.5 y; the crossings invalidate Cox
regressions performed in both reports.[2, 8] Second, rates were not stable after 2003, as indi-
cated by the second WHIT report;[8] they increased until the end of the study period. Third,
although the second report states that in “SEER, a substantial drop in breast cancer in 2003 was
coincident with the decrease in menopausal hormone therapy in the United States,”[8] it fails
to address the issue previously noted[6]—breast cancer rates peaked before the 2003 study.
The current analysis further substantiates that claim: not only did this analysis show that rates
for invasive ductal carcinoma and invasive lobular carcinoma peaked before 2003, it showed
that all racial and age subgroups that had peaks did so before the 2001 peak in HRT prescrip-
tion rates.
Approximately 85% of women who participated in the WHIT trial are white, which is sub-
stantially higher than the 64% white women in the SEER population. Based on the parallelism
test, for both ductal and lobular carcinoma, Whites and Blacks differ significantly from each
other; thus some of the discrepancies between the WHIT trial and SEER based studies can be
partially explained by the differences in patient characteristics.
The cause of the decline remains unsettled. One possible contribution to a decline might be
chemoprevention, first recommended as respects Tamoxifen, for general use in 1998. The only
database available is a survey of patients, not physicians as to Tamoxifen therapy. A 2010
report showed that between 2000, 0.2% (0.13, 0.31%) and 2005, 0.8% (0.03–0.17%), only a
small fraction of women had taken the drug without definite differences over time.[23] Because
the FDA did not grant approval for this use of Tamoxifen until 2007, the quality of the data
before and after that date are dissimilar, precluding a valid analysis of tamoxifen use over the
period in question. The 2012 analysis showed that in 2010, 0.3% (0.001, 0.15%) of women 35–
79 y were taking Tamoxifen chemoprevention, which does not differ from the prior two
results.[24] Thus, although chemoprevention might have contributed to the observed decline
in breast cancer rates, it is very unlikely that it would have accounted for it entirely. Should the
factor be analyzed in the future, complexities would include the additional chemoprevention
strategies that have since been adopted.[25–29] Such an analysis, of course, unless it showed a
decline in chemoprevention, would be unable to explain the increase in breast cancer rates seen
in this study.
HRT prescription rates showed a dramatic drop from its 2001 peak. This marked decline
was not reflected in any of the other analyzed rates. Rates for both lobular and ductal breast
cancer showed a decline that began before the HRT peak, but then showed an increase, such
that by 2012 rates were similar to those seen in 2001, indicating there is no clear relationship
between HRT and breast cancer. Endometrial carcinoma rates increased, the opposite of what
would have been expected had exogenous hormones been of importance in that disease. Rates
Breast Cancer Rates, Hormone Replacement Therapy
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for women for femoral neck fractures, total hip replacements, myocardial infarctions, and cere-
bral infarctions, paralleled those of men, who received no HRT prescriptions, As mentioned
before, this lack of difference among the sexes argues against an effect on these disorders as
respects HRT; however, owing to the nature of population level data, a small effect or one lim-
ited to a subgroup of the population might not have been detected.
Supporting Information
S1 Table. Raw data and joinpoint calculated estimates and standard errors.
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